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Discussion Points. 27 
1. How can we predict antidepressant response? Researching genes in specific populations may be the 28 
answer 29 
2. FKBP5 is a regulator in the HPA axis that shows promise for predicting antidepressant response. What 30 
are the next steps? 31 
3. FKBP5 is a gene associated with epigenetic changes in those with childhood trauma and depression. 32 
Can it predict treatment? 33 
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ABSTRACT. 1 
 2 
FKBP5 gene variants may predict antidepressant treatment response in individuals with Major Depressive 3 
Disorder. PubMed and Web of Science were searched systematically for articles studying individuals who had 4 
received a diagnosis of Major Depressive Disorder (MDD) and were given antidepressant treatment. Inclusion 5 
criteria were studies that researched FKBP5 and its variants and focused on antidepressant treatment 6 
response. Previous studies support a potential underlying epigenetic mechanism, demethylation at FKBP5 7 
polymorphisms (rs1360780, rs3800373, rs9470080, and rs4713916) after experiencing childhood trauma, 8 
leading to increased hypothalamic-pituitary-adrenal (HPA) axis sensitivity and a propensity for the development 9 
of MDD. These polymorphisms informed the search, but additional polymorphisms (rs9380514, rs352428) were 10 
also considered. Studies conducted prior to 2008, reviews, meta-analyses, editorials, and non-research based 11 
articles were excluded. Studies examined in this article link FKBP5 polymorphisms (rs4713916) and FKBP5 12 
RNA levels with positive antidepressant response. Variants rs1360780, rs3800373, and rs9470080 were 13 
associated with both positive response and non-response or lack of remission. Variants rs9380514, rs352428, 14 
and rs936882 were associated with poor response to antidepressant treatment or non-remission. Further 15 
insights into the role FKBP5 plays in development and antidepressant treatment response may be aided by 16 
future studies focused on individuals who previously experienced childhood trauma and later developed MDD. 17 
 18 
Key Words: (Source: MeSH-NLM). Pharmacogenetics; Depressive Disorder, Major; Adult Survivors of Child 19 
Adverse Events  20 
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SUBTITLES FOR CONSIDERATION BY THE AUTHOR. 1 
 2 
Introduction 3 
 In 2018, approximately 17.7 million adults in the United States had suffered at least one major depressive 4 
episode,1 and a survey conducted by the Centers for Disease Control and Prevention (CDC) estimated 12.7 5 
percent of Americans aged 12 and over took antidepressant medication within the past month.2 Antidepressants 6 
used to treat Major Depressive Disorder (MDD) have historically varied in efficacy for different individuals. 7 
Prescription of these medications is often on a trial-and-error basis, delaying necessary treatment for patients.  8 
 9 
In an effort to improve the selection of an effective treatment, antidepressant pharmacotherapy has become 10 
one of the first ventures into pharmacogenetics, a field that aims to identify ideal therapies based on the patient’s 11 
genetic data. Companies including Myriad Genetics have developed genetic testing (GeneSight) to identify 12 
genetic polymorphisms that can be used to clinically predict antidepressant efficacy, and are currently being 13 
used in practice today. However, the research linking genetic polymorphisms to MDD and antidepressant 14 
efficacy have not yielded consistent results,3-5 and support from professional organizations including the 15 
American Psychiatric Association is lacking,6 suggesting further study in defined subpopulations may be 16 
necessary. Traditionally, studies have used race and ethnicity. Recent studies indicate that there may be several 17 
origins and subtypes of MDD, suggesting that a more appropriate subpopulation for genetic studies may be 18 
identified by a shared experience or other factors contributing to MDD development.7,8 19 
 20 
Increased hypothalamic-pituitary-adrenal (HPA) axis activity has been linked to depression in several 21 
studies.9,10 The glucocorticoid receptor plays a critical role in preventing a continued stress response mediated 22 
by the HPA axis after a threat has ended.11 FK506 binding protein 5 (FKBP5), a gene for a glucocorticoid 23 
receptor binding protein that regulates glucocorticoid receptor sensitivity within the HPA axis, has been identified 24 
as a probable predictor of antidepressant response and has a potential defined subpopulation for study, 25 
individuals who have experienced childhood trauma. FKBP5 variants located in regions of transcriptional 26 
regulation including rs1360780 undergo epigenetic alterations (demethylation) as a result of childhood trauma, 27 
and have been associated with MDD.11-14 In the proposed mechanism, decreased methylation of FKBP5 at 28 
transcriptional regions leads to upregulation of FKBP5, which decreases glucocorticoid receptor sensitivity by 29 
binding to its complex and preventing its translocation to the nucleus. This molecular interaction results in 30 
increased resistance and ultimately dysregulation of the HPA axis, predisposing individuals to developing 31 
MDD.11,15-20 Additionally, early studies in mice show that loss of FKBP5 reduces expression of excitatory 32 
glutamate receptors and increases the expression of GABA in the hippocampus, ultimately affecting long term 33 
potentiation and neuroplasticity.21 FKBP5 rs1360780 polymorphisms in individuals with MDD who experienced 34 
childhood trauma have also been associated with structural and functional differences within the brain, including 35 
reduced activity in the insula following emotional stimuli, and lower FKBP5 methylation levels have been linked 36 
with reduced gray matter concentration in the inferior frontal orbital gyrus bilaterally, an area associated with 37 
depressive symptoms.22-24 Other studied variants include the rs9296158, rs3800373, and rs9470080 38 
alleles.3,11,12, 25-28 39 
 40 
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This review will examine the epigenetically-modified FKBP5 variants associated with previously experienced 1 
childhood trauma and their potential to predict antidepressant response. Searching the literature for genetic 2 
variants associated with a pathophysiologic mechanism may yield insights into future research directions to 3 
identify successful treatments for specific subpopulations.  4 
 5 
Methods 6 
Search Strategy and Selection Criteria 7 
PubMed and Web of Science were searched for relevant articles. Titles and abstracts were analyzed manually 8 
for direct relevance to the hypothesis. Required inclusions were 1) focus on individuals diagnosed with unipolar 9 
MDD and 2) associations between FKBP5 variants and response to antidepressant treatment. FKBP5 10 
polymorphisms associated with childhood trauma and development of MDD were of particular interest, but 11 
polymorphisms that did not meet this criteria were also included. Other inclusion criteria were human-based 12 
studies that specifically researched the FKBP5 gene and its variants and antidepressant treatment response. 13 
 14 
Studies that were published prior to 2008, meta-analyses, literature reviews, consensus papers, editorials, and 15 
updates were excluded. Additionally, articles that were considered out-of-scope of this review included studies 16 
that used non-human models with a focus on neuronal differentiation, studies that focused on the interaction 17 
between FKBP5 and other genes, those that focused on FKBP5 variants and their impact on conditions other 18 
than MDD (e.g., anxiety disorders and bipolar disorder, high stress reactivity and stress hormone regulations), 19 
and those that did not differentiate between unipolar and bipolar depression in their patient sample. Studies that 20 
examined FKBP5 and MDD in older adults without a history of childhood maltreatment were also excluded.  21 
 22 
An initial search in PubMed for articles published between 2008-2018 with the search string “fkbp5” AND “major 23 
depression” yielded 32 results. Of these articles, 31 were excluded: 23 were out of scope as determined by the 24 
criteria above, 3 were review articles, 2 were meta-analyses, 2 were updates or reflections, and 1 was an 25 
editorial. The search string “fkbp5” AND “depression” AND “pharmacogenetics” yielded 10 results; 7 articles 26 
were excluded as 4 were determined to be out of scope, 2 were updates or reflections, and 1 was a meta-27 
analysis. The search string “antidepressant response” AND “fkbp5” yielded 13 results. Nine of these articles 28 
were excluded, with 4 out of scope, 2 reviews, 1 meta-analysis, 1 consensus paper, and 1 update. Due to the 29 
specificity of the search for the FKBP5 gene and its variants, utilizing MESH terms did not yield results within 30 
the inclusion criteria. 31 
 32 
Repeating the searches with Web of Science using “fkbp5” AND “major depression” published between 2008-33 
2018 yielded 112 findings, and one additional article for analysis. Using the search terms “fkbp5” AND 34 
“depression” AND “pharmacogenetics” yielded 14 results, and included 3 repeated findings. “Antidepressant 35 
response” AND “fkbp5” did not yield additional articles for analysis. In total, 7 articles were selected for inclusion 36 
in analysis.  37 
 38 
For the articles included in the analysis, the study characteristics and methods were extracted. The number of 39 
participants, methods used to assess depression symptoms, specific antidepressant treatments or algorithms, 40 
and methods used to assess treatment response were noted for each study. Articles were examined for 41 
International Journal of Medical Students – Review. 
5 
IJMS 
associations between antidepressant response and FKBP5 polymorphisms or mRNA levels. These findings 1 
were grouped by FKBP5 expression levels, polymorphisms previously found to be associated with childhood 2 
trauma and development of MDD, and polymorphisms that did not have previous evidence of association with 3 
childhood trauma and development of MDD. 4 
 5 
Results 6 
FKBP5 expression levels and several FKBP5 polymorphisms from various populations were studied in response 7 
to antidepressant treatment, as described in Table 1. Additionally, methods of assessing response are included 8 
within the table. 9 
 10 
Antidepressant treatment and FKBP5 expression levels 11 
Cattaneo et al.29 and Banach et al.30 examined FKBP5 expression levels following antidepressant treatment 12 
with conflicting results. Cattaneo et al.29 selected participants from the GENDEP trial for analysis. Leukocyte 13 
mRNA levels of FKBP5 and other candidate genes were measured using quantitative PCR, and FKBP5 14 
expression levels were normalized to the mean expression of reference genes including glyceraldehyde 3-15 
phosphate dehydrogenase, beta actin, and beta-2 microglobulin. The Pfaffl method, which accounts for 16 
differences in primer efficiencies, was used to compare FKBP5 expression with controls. Additionally, changes 17 
in FKBP5 mRNA levels were compared before treatment and after 8 weeks. 18 
 19 
FKBP5 mRNA levels in depressed patients were found to be higher than in controls (controls: 0.99±0.02; 20 
patients: 1.26±0.02; +27% change, p<0.0001). 51 patients responded to antidepressants, with 26 responding 21 
to escitalopram and 25 responding to nortriptyline. 23 patients did not respond to antidepressants, with 12 not 22 
responding to escitalopram and 11 not responding to nortriptyline. For all 74 patients, FKBP5 mRNA levels were 23 
1.26±0.02 prior to treatment, and 1.17±0.02 after 8 weeks of treatment. Successful antidepressant treatment, 24 
irrespective of drug class, reduced FKBP5 mRNA levels in depressed patients (no errors reported; -11% 25 
change, p<0.0001). There was no effect on FKBP5 levels in patients who did not respond to treatment (no 26 
errors reported; -2% change, p=0.45; response x time interaction: F=4.4, p=0.04; drug x time interaction: 27 
F=0.05, p=0.8). 28 
 29 
Banach et al.30 collected peripheral blood for isolation of RNA from leukocytes and a dexamethasone 30 
suppression test prior to the start of antidepressant treatment. Eight weeks after receiving treatment, a second 31 
blood sample was collected. FKBP5 gene expression level was analyzed using qPCR with 18S rRNA used as 32 
a reference gene. Differences in gene expression before and after treatment were compared using the non-33 
parametric Wilcoxon signed-rank test. 34 
 35 
Three patients were observed to have HPA axis dysregulation at the beginning of the study, and two had normal 36 
function following 8 weeks of treatment. No statistically significant difference in mean cortisol levels before and 37 
after 8 weeks of treatment was found (p=0.944). Following 8 weeks of antidepressant treatment, all participants 38 
experienced improvement in depressive symptoms and all but one were in remission. The mean HAM-D score 39 
value was 3.4±3.1 for patients taking sertraline and 5.0±2.4 for patients taking venlafaxine. There was no 40 
difference in gene expression of FKBP5 before and after antidepressant treatment (pre-treatment: max=16, 41 
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upper quartile=15, median=13.2, lower quartile=11.2, min=11; post-treatment: max=16.8, upper quartile=14.4, 1 
median=13.1, lower quartile=11.8, min=9.9; p=0.813). 2 
 3 
FKBP5 variants linked to childhood trauma in prior studies: rs1360780, rs3800373, rs9470080, and rs4713916 4 
Lekman et al.,31 Zobel et al.,32 Stamm et al.,33 and Fabbri et al.,34 found correlations between rs1360780, 5 
rs3800373, rs9470080, and rs4713916 and antidepressant response/non-response and remission. 6 
 7 
Lekman et al.31 determined FKBP5 genotype using Illumina Next Generation Sequencing. In the genotype 8 
association test to identify associations with antidepressant response, FKBP5 rs4713916 was shown to be 9 
significantly associated with remission (AA/GG genotype: OR=1.60, 95% CI: 1.04-2.43; AG/GG genotype: 10 
OR=1.47, CI: 1.15-1.88; p=0.049) but not treatment response (p>0.05) when studied in all ethnicities and 11 
corrected for multiple testing. Studying linkage disequilibrium patterns reveals that rs4713916 single nucleotide 12 
polymorphisms (SNP) may serve as the functional region of FKBP5. 13 
 14 
Zobel et al.32 examined five FKBP5 polymorphisms located in the same haplotype block including rs3800373, 15 
rs755658, rs1360780, rs1334894, and rs4713916. DNA samples were collected from whole blood and 16 
fluorescence-based allelic discrimination techniques were used for analysis. Comparison of FKBP5 genetic 17 
variants between the treatment group and controls and mean values of treatment response were compared 18 
using t-tests. 19 
 20 
FKBP5 variants rs3800373 (AA allele) and rs4713916 (GG allele), also associated with MDD diagnosis, 21 
demonstrated a decreased reduction in cortisol secretion after 4 weeks of treatment (rs3800373: pre-treatment 22 
mean=2211, errors not given; post-treatment mean=-426, errors not given; p=0.08; rs4713916: pre-treatment 23 
mean=1932, errors not given; post-treatment mean=-338, errors not given; p=0.04). These associations were 24 
insignificant with multiple testing. No significant changes were found in HAM-D scores. 25 
 26 
Stamm et al.33 determined FKBP5 rs1360780 genotypes. Cox regression analysis was used to analyze the 27 
interaction between genotype and antidepressant treatment. The FKBP5 rs1360780 C allele carriers were found 28 
to benefit from the standardized antidepressant treatment algorithm. Approximately 64.4% of patients 29 
undergoing the algorithm treatment reached remission compared to 38.8% of those in the usual treatment group 30 
(p<0.001). Patients who were rs1360780 TT allele carriers showed better treatment response with the first 31 
treatment step than CT/CC allele carriers (TT: 60.9%, CT/CC: 38.2%, p=0.03), but there was not a significant 32 
difference at the end of the treatment sequence (TT: 69.6%, CT/CC: 53.5%, p>0.05). After six weeks of 33 
treatment with one antidepressant, rs1360780 TT allele carriers were found to have significant improvement 34 
(HR=1.89, p<0.03). Additionally, rs1360780 TT allele carriers were more likely than CC/CT allele carriers to 35 
achieve remission (HR=0.52; p=0.01). 36 
 37 
Fabbri et al.34 analyzed genetic data from three original patient populations and the patients from the STAR*D 38 
sample to study the association of various candidate genes, including FKBP5, with remission, antidepressant 39 
response, and treatment resistance. The STAR*D sample, as described previously, was used for replication. 40 
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Effects of selected SNPs on antidepressant response, remission, and treatment resistance were tested using 1 
logistic regression models. 2 
 3 
Fabbri et al.34 examined FKBP5 polymorphisms and their association with four phenotypes: response to the 4 
treatment provided to the associated population, remission to the provided treatment, lack of response to 5 
escitalopram, and lack of remission when taking escitalopram. In the first European sample, FKBP5 rs3800373 6 
CC genotype and C allele were associated with a higher risk of non-response, although the results were 7 
nominally significant (genotype: p=0.046, OR=0.11, 95% CI: 0.005-0.68). Additionally, the rs3800373 CC 8 
genotype corresponded with treatment resistance, including lack of response (p=0.01 OR=5.15, CI: 1.47-18.87) 9 
and lack of remission (p=0.02, OR=6.44, CI: 1.51-35.34) when taking escitalopram. The rs3800373 CA 10 
genotype was only correlated with lack of remission when taking escitalopram in the second European sample 11 
(p=0.04, OR=2.93, CI: 1.07-8.55), and was associated with a higher risk for lack of response (p=0.01 OR=0.28, 12 
CI: 0.09- 0.73) and remission (p=0.03, OR=0.27, CI: 0.07-0.83) in the ITAS sample. The rs3800373 C allele 13 
was linked with higher risk of non-response in the first European sample (p=0.03, OR=0.50, CI: 0.26-0.93) and 14 
the second European sample (p=0.02, OR=0.52, CI: 0.29-0.91). The rs3800373 C allele was also associated 15 
with lack of response to escitalopram (p=0.005, OR=2.35, CI: 1.29-4.27) and lack of remission when taking 16 
escitalopram in the second European sample (p=0.002, OR=3.07, CI: 1.52-6.42).  17 
 18 
The rs1360780 TT genotype was associated with a higher risk of non-response to venlafaxine (p=0.02, 19 
OR=0.24, CI: 0.065-0.71), lack of response to escitalopram (p=0.01, OR=4.27, CI: 1.40-13.04), and lack of 20 
remission when taking escitalopram (p=0.02, OR=4.76, CI: 1.36-19.77) in the second European sample. In the 21 
ITAS sample, the rs1360780 CT genotype correlated with a higher risk of non-response to antidepressants 22 
(p=0.002, OR=0.22, CI: 0.08-0.55) and non-remission (p=0.003, OR=0.17, (CI: 0.05-0.52). The rs1360780 T 23 
allele corresponded with lack of response to venlafaxine in the second European sample (p=0.02, OR=0.60, 24 
CI: 0.38-0.93) and treatment in the ITAS sample (p=0.009, OR=0.40, CI: 0.20-0.78). Additionally, in the second 25 
European sample, the T allele was associated with lack of response (p=0.01, OR=1.95, CI: 1.16-3.26) and lack 26 
of remission (p=0.01, OR=2.05, CI: 1.17-3.60) when taking escitalopram. In the ITAS sample, the T allele was 27 
linked with a higher risk of non-remission (p=0.04, OR=0.45, CI: 0.20-0.95).  28 
 29 
In the second European sample, the rs9470080 TT genotype was associated with lack of remission when taking 30 
escitalopram (p=0.0469, OR=3.96, CI: 1.06-16.65). The rs9368882 TT SNP, found to be in high linkage 31 
disequilibrium with rs9470080 (R2=0.67), was correlated with a higher risk of non-remission in patients taking 32 
citalopram in the STAR*D replication study (p=0.035, OR=0.82, CI: 0.69-0.98). 33 
 34 
Fabbri et al.34 also provided another perspective of their results, as described within this paragraph. All findings 35 
showed consistent effects in two or more of the groups that responded to antidepressant treatment, were in 36 
remission, or did not respond or achieve remission while taking escitalopram. In the second European sample, 37 
rs3800373 AA genotype/A allele showed some evidence of response and remission (no OR or CI reported; 38 
p=0.03 for the allelic repeated-time analysis). The rs1360780 CC genotype/C alelle were linked with response 39 
to venlafaxine and remission, and confirmed using repeated time analysis (allele: no OR or CI reported, p=0.01 40 
and gen..otype: no OR or CI reported, p=0.0059). In the ITAS population, the rs1360780 CC genotype/C alelle, 41 
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rs3800373 AA allele, and rs9470080 CC genotype were associated with antidepressant response and remission 1 
(rs1360780 genotype: p=0.014, no OR or CI reported and allele: p=0.001; rs3800373 AA allele: p=0.003, no 2 
OR or CI reported; significance for rs9470080 not given).  3 
 4 
FKBP5 variants not linked to childhood trauma in prior studies: rs9380514, rs352428 5 
Ellsworth et al.35 found additional single nucleotide polymorphisms that may play a role in functional regulation 6 
of FKBP5. Ellsworth et al.35 utilized Sanger and Illumina Next Generation genetic sequencing to sequence 7 
FKBP5 in lymphoblastoid cells. FKBP5 variants were identified using Next Generation sequencing, and 340 8 
SNPs met criteria for analysis including having a minor alley frequency of 1% or higher, passing the Illumina 9 
Golden Gate genotyping quality control criteria, and absence of significant deviation from Hardy-Weinberg 10 
equilibrium. The effect of different SNPs on response and remission were analyzed using logistic regression 11 
models and were adjusted for potential population stratification. Electrophoresis mobility shift and reporter gene 12 
assays were performed on nuclear extracts from two glioblastoma cell lines and lymphoblastoid cells. 13 
 14 
Association analysis for the Mayo PGRN-AMPS patients found that FKBP5 rs9380514 (A allele) corresponded 15 
to poor antidepressant response at the last visit (P=0.0249, OR=0.65 (95% CI: 0.44-0.95)) and after 8 weeks 16 
(P=0.0175, OR=0.59 (CI: 0.38-0.91)). SNP 35758265 (no rs number available) corresponded with a percentage 17 
change in QIDS-C after the last visit (no mean or SEM provided; Spearman: 0.09, P=0.042). Twenty-two SNPs 18 
were affiliated with remission after 8 weeks at the last visit, 15 trans FKBP5 expression quantitative trait loci 19 
(eQTL) SNPs corresponded to antidepressant response after 8 weeks or at the last visit, and 6 FKBP5 eQTL 20 
SNPs were associated with remission after 8 weeks of treatment or at the last visit; however, none of these 21 
associations were found to be significant after correcting for multiple testing. Association analysis replicating 6 22 
SNPs from the STAR*D study found FKBP5 eQTL SNP rs352428 to be associated with poor antidepressant 23 
response after 6 to 8 weeks (P=0.05, OR=0.74, CI: 0.54–1.00). There were no associations found between 24 
rs1360780, rs3800373, and rs4713916 and antidepressant response (no statistical information provided). 25 
Electrophoresis mobility shift and reporter gene assays confirmed that rs352428 (A/G alleles) may play a 26 
potential role in regulation of transcription. 27 
 28 
Discussion 29 
This review examined studies that evaluated FKBP5 polymorphisms and expression levels and their association 30 
with antidepressant response. Studies that included polymorphisms previously linked to a potential underlying 31 
epigenetic mechanism of development of MDD in individuals who experienced childhood trauma were of 32 
particular interest. FKBP5 is a promising biomarker due to the multitude of evidence associating a specific 33 
environmental factor with increased susceptibility to development of MDD.3,11-15,19,20,25-28 34 
 35 
Cattaneo et al.29 and Banach et al.30 examined FKBP5 RNA expression levels following antidepressant 36 
treatment. While Cattaneo et al.29 found decreased RNA expression following treatment, Banach et al.30 failed 37 
to observe significant differences. Potential explanations for this disparity, as noted by Banach et al.,30 include 38 
the lack of HPA axis dysregulation observed in the studied population. Additionally, Banach et al.30 studied a 39 
smaller group of individuals (30 participants) compared to the 74 patients studied by Cattaneo et al.,29 which 40 
likely resulted in lower statistical power for the former. Both studies contain relatively small sample sizes, and a 41 
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larger group of participants may be necessary to observe the true effects of antidepressants on FKBP5 levels. 1 
Of note, Banach et al.30 observed a trend of decreased FKBP5 mRNA expression after administration of 2 
sertraline and an increase of expression after venlafaxine therapy, although significance was not reached.  3 
 4 
Variants of the FKBP5 rs1360780 allele were associated with both successful antidepressant response and 5 
remission and non-response. Stamm et al.33 found that the rs1360780 TT allele carriers were more likely to 6 
respond to a standardized algorithm antidepressant treatment regimen and experience more remission 7 
compared to CT/CC allele carriers. However, a greater percentage of CT/CC allele carriers also achieved 8 
remission in the algorithm treatment group compared to treatment as usual. In contrast, Fabbri et al.34 found 9 
the TT/CT genotypes to be associated with non-response to antidepressants and lower rates of remission. 10 
These findings suggest the mode of treatment is significant, and genotype alone may not account for differences 11 
in antidepressant response. Fabbri et al.34 found that the rs1360780 CC genotype/C allele had nominal 12 
associations with response to venlafaxine and remission, and decreased risk of treatment resistant depression 13 
in a European and ITAS population. The data from these two studies suggest that both the TT allele and CT/CC 14 
allele may have a better response to different treatments. The positive association with FKBP5 polymorphisms 15 
and response to different treatments strongly supports that it plays some role in treatment response. However, 16 
the differences in treatment provided within the two studies makes it difficult to parse out the true impact of 17 
genotype on treatment response, and future studies might consider comparing rs1360780 polymorphisms and 18 
antidepressant response to a wider range of different treatment options and drug classes, including a placebo, 19 
within the same population. 20 
 21 
Fabbri et al.34 also found the rs3800373 AA genotype/A allele showed some evidence of response and 22 
remission in two populations, and the CC genotype/C allele was associated with non-response and lack of 23 
remission. Additionally, the rs9470080 CC allele was associated with antidepressant response and remission, 24 
and the TT genotype was correlated with decreased remission in patients receiving escitalopram. Also 25 
mentioned by Fabbri et al.34 as an interesting finding, the closely-linked rs9368882 was associated with non-26 
remission in patients who received citalopram. Although some of these findings were positive, Fabbri et al.34 27 
noted the associations were nominal. Previous studies have similarly linked these polymorphisms to increased 28 
susceptibility of MDD in individuals who experienced childhood trauma, suggesting a basis for the 29 
association.3,28 The utilization of three study populations strengthened the likelihood of finding a true 30 
association. However, relatively small sample sizes may have prevented strong significant associations from 31 
being discovered. 32 
 33 
Zobel et al.32 found associations between the FKBP5 rs3800373 AA genotype and rs4713916 and decreased 34 
reduction in cortisol secretion after treatment, suggesting a correlation with non-response to antidepressants. 35 
However, no significant changes were found in HAM-D scores and these associations were insignificant with 36 
multiple testing. Interestingly, both the rs3800373 AA genotype and rs4713916 were also associated with MDD 37 
diagnosis in the study. Non-response to antidepressant treatment conflicts with the positive rs3800373 AA 38 
genotype association found by Fabbri et al..34 However, the difference in these findings may be due to small 39 
effect sizes, as Zobel et al.32 had approximately half of the study population drop out. It should also be noted 40 
that those that tended to drop out had a greater average number of depressive episodes and likely were more 41 
International Journal of Medical Students – Review. 
10 
IJMS 
treatment resistant. This potentially skews their data toward more favorable results, although none were found. 1 
Strengths of the study include the use of a dex/CRH test as a biological indicator of antidepressant response. 2 
As noted by Zobel et al.32 and Lekman et al.,31 using standardized survey measures to determine response and 3 
non-response may be another explanation for disparities in treatment response found in the same 4 
polymorphisms. 5 
 6 
Lekman et al.31 found rs4713916 was shown to be significantly associated with remission (p=0.049) but not 7 
treatment response when studied in all ethnicities and corrected for multiple testing. Zobel et al.32 also found a 8 
lack of associated antidepressant response, but the study methods did not account for associations with 9 
remission. The study of linkage disequilibrium patterns by Lekman et al.31 showed that the rs4713916 SNP may 10 
serve as the functional region of FKBP5, and additional molecular studies may shed light on its involvement in 11 
pathogenesis. 12 
 13 
Ellsworth et al.35 found two additional SNPs, rs9380514 in the Mayo PGRN-AMPS study and rs352428 in the 14 
STAR*D study, that may play a role in functional regulation of FKBP5. Both polymorphisms were found to be 15 
associated with poor antidepressant response. However, the study failed to name the number of responders 16 
and non-responders, as well as the QIDS-C score that constituted poor response. Although Ellsworth et al.35 17 
found several SNPs that were associated with response and remission, none were found to be significant after 18 
multiple testing. The lack of significance may be attributed to limited sample size. To the author’s knowledge, 19 
rs9380514 and rs352428 have not been studied in individuals with MDD who experienced childhood trauma, 20 
but could potentially be examined in future studies. Establishing a molecular mechanism for rs352428 (A/G 21 
alleles), a polymorphism associated with transcriptional regulation including transcription factor binding and 22 
silencing, may strengthen evidence for its involvement in MDD and treatment response. 23 
 24 
A major limitation of many of the studies included in this review were their reports of nominal observed effects, 25 
stating that the lack of statistical power was likely due to small sample sizes and lack of heterogeneity. As noted 26 
by Zimmerman et al.28 and Hahle, Merz, Meyners, and Hausch,36 existing genome wide association studies 27 
have likely been statistically underpowered to identify FKBP5 associations due to many of the associations 28 
being linked with specific environmental factors, including childhood trauma. Additionally, Ising et al.37 notes the 29 
importance of considering subgroups that may respond to particular treatments due to shared pathology. 30 
Existing studies on molecular mechanisms of the pathogenesis of MDD via increased HPA axis activity point to 31 
a particular population for further study, individuals who have experienced childhood trauma.11,14,16-19 Data 32 
supporting the association between polymorphisms and treatment response might be strengthened by 33 
specifically focusing on these individuals, as there have been demonstrated lower methylation levels at many 34 
of the same foci involved in antidepressant response. Both the rs1360780 A/T allele and the CC allele have 35 
been associated with susceptibility of MDD in individuals who experienced childhood trauma, and further study 36 
in this specific subpopulation may yield findings of greater significance.12,13,28 37 
 38 
An additional limitation of the studies is the limited clinical relevance of the data. Specific genotypes have not 39 
been associated with successful treatment using a specific antidepressant class. Ideally, FKBP5 polymorphisms 40 
could be used to predict what treatment would result in the best response for a specific population of patients. 41 
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The broad associations in these studies fail to inform treatment decisions in medical care. Another criticism of 1 
these studies, particularly the STAR*D trial, is their lack of a placebo treatment option, and therefore it is 2 
unknown whether remission would have occurred without antidepressants. Additionally, studies took different 3 
approaches to offering treatment. Some utilized a standard algorithm while others allowed physicians 4 
prescribing choice. While the presence of associations between FKBP5 and different treatments strengthens 5 
the evidence for its use as a potential biomarker, a blinded randomized study looking at different treatment 6 
responses to multiple classes of antidepressants would be ideal. 7 
 8 
As demonstrated by the number of positive associations with FKBP5 polymorphisms and antidepressant 9 
response in various study designs, it is likely that with an appropriate study population significant association 10 
can be discovered. Prior research linking both morphological changes within the brain and a probable molecular 11 
mechanism due to epigenetic changes suggests individuals who have experienced childhood trauma are an 12 
ideal population for future study. Focused future study on shared and newly discovered polymorphisms linking 13 
FKBP5 with MDD and antidepressant response may yield findings of clinical significance and further 14 
personalized psychiatric treatment.  15 
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FIGURES AND TABLES. 1 
 2 
Table 1. Studies that Examined Antidepressant Response and FKBP5 Gene Expression/Polymorphisms  3 
 4 
Author Genetic 
variant or 
gene 
expressio
n 
Population MDD 
criteria 
Antidepressant Assessment of 
response 
Banach 
et al. 
(2017)30 
Leukocyte 
FKBP5 
gene 
expression  
30 female patients age 
18-60 from the 
Department of Adult 
Psychiatry at Poznan 
University of Medical 
Sciences 
DSM-IV 
and 
HAM-D 
 
Moderate 
severity 
Participants were drug 
free at least 6 months 
prior to entering study 
 
Sertraline (50-150 mg) 
or Venlafaxine (75-225 
mg) 
Improvement in 
depressive 
symptoms, as 
determined by  
>50% reduction in 
HAM-D 
 
Remission 
determined by  
HAM-D <8 
Cattaneo 
et al. 
(2013)29 
Leukocyte 
FKBP5 
mRNA 
levels 
31 males and 43 
females from the 
GENDEP trial (811 
adult outpatients; 296 
men and 514 women 
from 9 psychiatric 
center in 8 European 
countries) age 19-72 
DSM-IV 
 
Moderate 
severity 
Selected subset did not 
take medication for at 
least 2 weeks prior to 
entering the trial 
 
Nortriptyline (50-150mg 
daily) or Escitalopram 
(10-30 mg daily) for 12 
weeks 
Assessed weekly 
for depression 
symptom severity 
and antidepressant 
response using 
MADRS, HAM-D, 
and BDI 
 
Successful 
response:  
>50% reduction in 
MADRS score 
from baseline 
through week 12 
Lekman 
et al. 
(2008)31 
rs4713916 1,809 patient samples 
age 18-75 from 
STAR*D study that 
were determined to 
have MDD 
 
Patients were 
compared to 739 
controls that were 
obtained from the 
Rutgers Cell Repository 
and were determined 
not to have a mental 
health condition 
DSM-IV Citalopram as a first-
line antidepressant; 
data up until 14 weeks 
was used for analysis 
to account for patients 
that were resistant and 
required a second 
treatment 
QIDS-C to 
measure 
antidepressant 
response at each 
visit and at 14 
weeks; patients 
were determined to 
have responded to 
treatment if they 
had at least a 50% 
reduction in their 
QIDS-C score and 
patients 
determined to be in 
remission had a 
QIDS-C score ≤5 
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Zobel et 
al. 
(2010)32 
rs3800373,  
rs755658,  
rs1360780, 
rs1334894,  
rs4713916 
110 German patients 
age 18-60 with 
recurrent unipolar 
depression, as 
determined by DSM-IV, 
after accounting for 
drop-outs and 284 
controls 
DSM-IV Tapered off previous 
antidepressants prior to 
start of study 
 
Citalopram (20-40 mg) 
with or without 
Lorazepam 
HAM-D at baseline 
(Day 8) and Day 
36 
 
Antidepressant 
response 
assessed using 
dexamethasone-
suppressed 
corticotropin-
releasing hormone 
test 
Stamm et 
al. 
(2016)33 
rs1360780 298 patients age 18-70 
with MDD who were 
recruited from hospitals 
and were participating 
in the German 
Algorithm Project 
(GAP3) or the Zurich 
Algorithm Project 
DSM-IV 
and 
HAM-D 
score 
≥15 
Patients in both studies 
received a stepwise 
treatment regimen 
guided by an algorithm 
(n=171) or standard 
treatment (n=127). 
 
Participants first 
received one of four 
antidepressant classes 
(venlafaxine, sertraline, 
amitriptyline, or 
reboxetine) and 
maintained the same 
dosage for at least 4 
weeks. Patients who 
did not respond (HAM-
D score reduction 
<30%), received 
lithium, an increased 
dose of the same 
medication, or change 
to a different 
antidepressant class.  
 
Patients who did not 
respond to the 
escalated step 
continued with other 
options until receiving 
electroconvulsive 
therapy.  
 
For the standard 
treatment group, 
physicians were 
allowed to choose the 
appropriate treatment 
Assessed for 
antidepressant 
response at the 
start of the study 
and every two 
weeks throughout 
the treatment 
period using HAM-
D 
 
Patients with a 
HAM-D score less 
than 10 were 
determined to be in 
remission 
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Fabbri et 
al. 
(2018)34 
rs3800373 
rs1360780 
rs9470080 
Three original 
populations: 
1) First European 
sample 
consisted of 
357 patients 
diagnosed with 
MDD and 
received 
antidepressants 
 
2) Second 
European 
sample 
contained 218 
patients with 
moderate or 
severe MDD 
 
3) Italian sample 
(ITAS) 
consisting of 96 
patients with 
MDD 
 
STAR*D sample was 
used for replication 
1) DSM-
IV 
 
2) DSM 
IV and 
MADRS 
score 
>22 
 
Moderate 
or severe 
MDD 
 
3) DSM 
IV and a 
HAM-D 
score 
≥13 
First European Sample: 
Unspecified 
antidepressants  
 
Second European 
Sample: Venlafaxine 
then Escitalopram (if no 
response after 6 
weeks) 
 
Italian Sample: 
Unspecified 
antidepressants  
First European 
Sample: 
HAM-D after 4 
weeks of treatment 
 
Second European 
Sample: MADRS 
was used to 
evaluate each 
patient’s symptoms 
of depression 
biweekly from the 
start of the study 
through week 12 
 
Italian Sample: 
HAM-D; evaluated 
weekly from 
beginning of the 
study through 
week 8 
 
For the three 
original patient 
populations, 
response to 
antidepressant 
treatment or 
remission was 
evaluated at week 
4 or 6; response 
was determined by 
a decrease of 50% 
or greater in the 
HAM-D or MADRS 
and remission was 
a score of less 
than or equal to 7 
on the HAM-D or 
less than 10 on the 
MADRS 
Ellsworth 
et al. 
(2013)35 
rs9380514 
 
SNP 
35758265 
(no rs 
number 
available)  
 
rs352428 
512 patients in the 
Mayo  
Clinic 
Pharmacogenomics 
Research Network-
Antidepressant 
Medication 
Pharmacogenomic 
Study (Mayo PGRN-
AMPS) and a 
replication study of 950 
patients from the 
STAR*D study 
HAM-D 
score 
≥14 
Citalopram or 
escitalopram 
Treatment 
response was 
assessed at 4 and 
8 weeks using the 
QIDS-C, and 
patients with ≥50% 
reduction in QIDS-
C score were 
determined to have 
responded. 
Patients with a 
QIDS-C score less 
than 5 were 
determined to be in 
remission  
 1 
 2 
 3 
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Legend: Major Depressive Disorder (MDD); (DSM-IV) Montgomery-Asberg Depression Rating Scale 1 
(MADRS); Hamilton Depression Rating Scale (HAM-D); Beck Depression Inventory (BDI); Sequenced 2 
Treatment Alternatives to Relieve Depression (STAR*D); Quick Inventory of Depressive Symptomatology-3 
Clinician rating scores (QIDS-C) 4 
